Vildagliptin
- Generic Name
- Vildagliptin
- Brand Names
- Galvus, Jalra, Xiliarx
- Drug Type
- Small Molecule
- Chemical Formula
- C17H25N3O2
- CAS Number
- 274901-16-5
- Unique Ingredient Identifier
- I6B4B2U96P
- Background
Vildagliptin (LAF237) is an orally active antihyperglycemic agent that selectively inhibits the dipeptidyl peptidase-4 (DPP-4) enzyme. It is used to manage type II diabetes mellitus, where GLP-1 secretion and insulinotropic effects are impaired. By inhibiting DPP-4, vildagliptin prevents the degradation of glucagon-like peptide 1 (GLP-1) and glucose-dependen...
- Indication
Vildagliptin is indicated in the treatment of type II diabetes mellitus in adults. As monotherapy, vildagliptin is indicated in adults inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to contraindications or intolerance. It is also indicated as dual therapy in combination with metformin, a sulphonylurea, or a thi...
- Associated Conditions
- Type 2 Diabetes Mellitus
- Associated Therapies
- -
A Study to Assess the Effects of DPP-4 Inhibition on Insulin Sensitivity in Type 2 Diabetes
- Conditions
- First Posted Date
- 2006-07-13
- Last Posted Date
- 2012-05-07
- Lead Sponsor
- Novartis
- Target Recruit Count
- 12
- Registration Number
- NCT00351546
Long-Term Safety Study of Vildagliptin in Patients With Type 2 Diabetes
- Conditions
- First Posted Date
- 2006-05-12
- Last Posted Date
- 2009-01-07
- Lead Sponsor
- Novartis
- Target Recruit Count
- 150
- Registration Number
- NCT00325429
- Locations
- 🇯🇵
Novartis Pharmaceuticals, Tokyo, Japan
To Assess the Efficacy and Safety of Vildagliptin as Add-on Therapy to Sulfonylurea in Patients With Type 2 Diabetes Inadequately Controlled With Sulfonylurea Monotherapy
- Conditions
- First Posted Date
- 2006-05-12
- Last Posted Date
- 2007-05-14
- Lead Sponsor
- Novartis
- Target Recruit Count
- 200
- Registration Number
- NCT00325117
- Locations
- 🇯🇵
Novartis Pharmaceuticals, Tokyo, Japan
A Study to Evaluate the Effects of Vildagliptin on the Insulin Response to Glucose in Subjects With Pre-diabetes
- Conditions
- First Posted Date
- 2006-04-07
- Last Posted Date
- 2016-11-18
- Lead Sponsor
- Novartis
- Target Recruit Count
- 20
- Registration Number
- NCT00312130
- Locations
- 🇺🇸
University of Washington, Seattle, Washington, United States
A 56-Week Extension to a Clinical Study to Assess the Efficacy and Safety of Vildagliptin Compared to Placebo in Drug Naive Patients With Type 2 Diabetes and Mild Hyperglycemia
- Conditions
- First Posted Date
- 2006-03-08
- Last Posted Date
- 2017-08-02
- Lead Sponsor
- Novartis
- Target Recruit Count
- 150
- Registration Number
- NCT00300287
A Clinical Study to Assess the Effect of Vildagliptin on Beta Cell Function in Drug Naive Patients With Type 2 Diabetes
- First Posted Date
- 2005-12-01
- Last Posted Date
- 2020-12-17
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 59
- Registration Number
- NCT00260156
- Locations
- 🇨🇭
Novartis Pharmaceuticals, Basel, Switzerland
A Clinical Study to Assess the Efficacy and Safety of Vildagliptin in Patients With Type 2 Diabetes
- Conditions
- First Posted Date
- 2005-10-13
- Last Posted Date
- 2012-05-02
- Lead Sponsor
- Novartis
- Target Recruit Count
- 291
- Registration Number
- NCT00238498
Efficacy and Safety of Vildagliptin in Subjects With Impaired Glucose Tolerance
- Conditions
- First Posted Date
- 2005-10-12
- Last Posted Date
- 2012-05-07
- Lead Sponsor
- Novartis
- Target Recruit Count
- 171
- Registration Number
- NCT00237250
- Locations
- 🇺🇸
Novartis Pharmaceuticals, East Hanover, New Jersey, United States
Vildagliptin Compared to Pioglitazone in Combination With Metformin in Patients With Type 2 Diabetes
- Conditions
- First Posted Date
- 2005-10-12
- Last Posted Date
- 2017-02-07
- Lead Sponsor
- Novartis
- Target Recruit Count
- 588
- Registration Number
- NCT00237237
- Locations
- 🇩🇪
Investigative Centers, Nurnberg, Germany
🇺🇸Novartis Pharmaceuticals, East Hanover, New Jersey, United States
Extension to a Study on the Efficacy and Safety of Vildagliptin in Combination With Glimepiride in Patients With Type 2 Diabetes
- Conditions
- First Posted Date
- 2005-08-30
- Last Posted Date
- 2017-03-01
- Lead Sponsor
- Novartis
- Target Recruit Count
- 345
- Registration Number
- NCT00138580
- Locations
- 🇺🇸
Novartis Pharmaceuticals, East Hanover, New Jersey, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.